Comparative Polyclonal Antithymocyte Globulin and Antilymphocyte/Antilymphoblast Globulin Anti-Cd Antigen Analysis by Flow Cytometry

Bourdage, James S.; Hamlin, D. M.

doi:10.1097/00007890-199504000-00020

Cited by 79 publications

(76 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 Some in vitro studies of differences between hATG and rATG formulations have been reported previously, but the scope of such studies was limited and the relevance of the observations in humans remains unclear. 7,8 In view of the marked differences in the clinical outcomes in our randomized clinical study, we here expand on our findings in this unique cohort of patients, in order to understand mechanistic differences underlying the effects of these two biologics. As serum sickness (SS) is a complication of animal anti-serum infusion, we also investigated immunological changes associated with this syndrome in ATG-treated patients.…”

Section: Introductionmentioning

confidence: 94%

In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 94%

In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia

et al. 2014

View full text Add to dashboard Cite

show abstract

“…ATG preparations are obtained by injecting rabbits or horses with human thymic cells or lymphocytes and the subsequent isolation and purification of antibodies against human cells. They contain antibodies targeting numerous membrane antigens, some of which are solely present on T-cells, such as CD3, CD4 or CD8, whereas others, like the adhesion molecules CD11b and CD18, are also found on other circulating cells [28]. Initially, the treatment induces a rapid and profound lymphopaenia through several Fc-receptor-dependent mechanisms, such as complementdependent cytolysis, cell-mediated antibody-dependent cytolysis, as well as opsonisation and phagocytosis by macrophages.…”

Section: Induction Therapymentioning

confidence: 99%

Immunosuppressive therapy after human lung transplantation

Knoop¹,

Haverich²,

Fischer³

2003

Eur Respir J

View full text Add to dashboard Cite

numbers of lung transplantation (LTx) were performed with or without induction therapy with antilymphocyte antibodies, monoclonal anti-CD3 antibody or anti-interleukin-2-receptor monoclonal antibodies. It remains to be established if induction therapy after LTx is beneficial or deleterious for long-term graft and patient survival.The vast majority of lung transplant recipients receive a triple-drug maintenance regimen including a calcineurin inhibitor, a cell-cycle inhibitor and steroids. Equal proportions receive cyclosporin A (CsA) and tacrolimus (Tac). There is also a trend to prescribe mycophenolate mofetil (MMF) instead of azathioprine (Aza). Steroid withdrawal is uncommon even 5 yrs after transplantation.The superiority of Tac over CsA as a maintenance agent has not been established to date, and the administration of MMF instead of Aza in combination with CsA and steroids did not improve graft or patient survival in a recent international, prospective, randomised, controlled trial.Shift from cyclosporin A to tacrolimus has emerged as the first treatment step of refractory acute rejection followed by high-dose steroids or antilymphocyte agents, total lymphoid irradiation or photopheresis. The treatment of chronic rejection remains deceptive and includes varied strategies such as modification of the maintenance regimen, addition of inhaled immunosuppressants and/or total lymphoid irradiation and photopheresis. Eur Respir J 2004; 23: 159-171.

show abstract

“…While complete depletion of T cells from bone marrow increases the risk of PTLD, methods that concomitantly remove B cells (ie anti-B-cell antibodies, counterflow elutriation, and CD34 positive selection) may have a protective effect. [15][16][17] In fact, ALG contains significant anti-B-cell antibody titers 34 and has an antiproliferative effect on B cells in vitro. 35 Thus, it is possible that ALG could have had a protective effect in our study by removing EBV-infected B cells, although immunophenotyping data did not demonstrate statistically significant differences in B-cell recovery early post BMT for ALG-vs ATG-treated patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation

Lynch

Vasef

Comito

et al. 2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:T cell depletion (TCD) of marrow is a proven method of graft-versus-host disease (GVHD) prophylaxis in allogeneic bone marrow transplantation (BMT). Nonetheless, TCD is associated with an increased risk of developing post transplant lymphoproliferative disorder (PTLD). Between 1986 and 1998, 241 pediatric patients at the University of Iowa underwent BMT using ex vivo TCD of marrow from mismatched related or matched unrelated donors. Additional GVHD prophylaxis included antithymocyte globulin (ATG) or anti lymphocyte globulin (ALG) post transplant (in vivo TCD). A total of 30 cases of PTLD were identified based upon a combination of clinical, histological, and immunological features. Nearly all cases occurred within 3 months post BMT. A statistically significant increase in PTLD incidence was noted for patients treated with ATG vs ALG (33 vs 9%). While grade I-II acute GVHD was more common in patients receiving ATG vs ALG, no difference in grade III-IV GVHD or overall survival was noted between the two groups. Assessment of immune recovery at various times post BMT revealed significantly fewer T cells in the ATG-treated group, suggesting the deleterious effect of ATG may be due to excessive depletion of donor-derived Epstein-Barr virus-specific cytotoxic T cells. Thus, caution should be exercised in the use of anti-T-cell antibody therapy for additional GVHD prophylaxis in the setting of TCD BMT.

show abstract

Comparative Polyclonal Antithymocyte Globulin and Antilymphocyte/Antilymphoblast Globulin Anti-Cd Antigen Analysis by Flow Cytometry

Cited by 79 publications

References 0 publications

In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia

In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia

Immunosuppressive therapy after human lung transplantation

Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation

Contact Info

Product

Resources

About